Painceptor Pharma Corp. To Accelerate ASICS Pain Therapeutics Development With NRC-IRAP Contribution
Montreal, Canada – February 7, 2006 - PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, today announced it will receive $480,000 in the form of a contribution agreement from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP).